Affordable Access

deepdyve-link
Publisher Website

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Authors
  • Collinson, Fiona
  • Hutchinson, Michelle
  • Craven, Rachel A
  • Cairns, David A
  • Zougman, Alexandre
  • Wind, Tobias C
  • Gahir, Narinder
  • Messenger, Michael P
  • Jackson, Sharon
  • Thompson, Douglas
  • Adusei, Cybil
  • Ledermann, Jonathan A
  • Hall, Geoffrey
  • Jayson, Gordon C
  • Selby, Peter J
  • Banks, Rosamonde E
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Sep 15, 2013
Volume
19
Issue
18
Pages
5227–5239
Identifiers
DOI: 10.1158/1078-0432.CCR-13-0489
PMID: 23935036
Source
Medline
License
Unknown

Abstract

This study shows a discriminatory signature comprising mesothelin, FLT4, AGP, and CA-125 as potentially identifying those patients with EOC more likely to benefit from bevacizumab. These results require validation in further patient cohorts.

Report this publication

Statistics

Seen <100 times